8-K ·Filed Aug 13, 2026

AGEN

AGENUS INC
NEUTRAL
Impact 2/10
Horizonmonths Processed1mo ago SEC0001193125-26-347518
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine CEO compensation grant with no immediate trading signal. The performance hurdles are extremely high (3x-8x current stock price), making dilution unlikely in the near term. Monitor next quarterly results for pipeline progress that could drive the stock toward the first vesting threshold.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d ⚠ clustered
AGEN ▼ -0.86% at T+20d
NEUTRAL call ✗ call lost -0.86% · α vs SPY +0.89% · entry $7.00 → $6.94
Next anchor: T+60d in 5w
Latest observation: T+32 +20.49% FF3 residual α
Entry anchored
Aug 12, 07:48 PM ET
via 1-min bar
T+1d
+4.57%
call +4.57% · α +4.77%
$7.32
settled 7w ago
T+5d
+7.00%
call +7.00% · α +8.96%
$7.49
settled 6w ago
T+20d
-0.86%
call -0.86% · α +0.89%
$6.94
settled 22d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Agenus granted Chairman/CEO Garo Armen a one-time performance-based stock option award of 1,971,500 options with a $7.78 exercise price (above the current closing price). The options vest in five tranches tied to stock price targets of 3x to 8x the exercise price, with a minimum three-year service requirement. This is a routine compensatory arrangement with no departure or financial impact, making it neutral for the stock.

Key Facts

  • CEO Garo Armen received 1,971,500 performance-based stock options with a 10-year term
  • Exercise price set at $7.78 per share, above the August 10, 2026 closing price
  • Options vest in five tranches at 3x, 4x, 5x, 6x, and 8x the measurement price
  • Minimum three-year service requirement; no acceleration on change in control
  • Award approved by Compensation Committee with independent consultant Aon Talent Solutions

Financial Impact

No immediate financial impact; potential dilution of up to 1,971,500 shares if all options vest and are exercised, but vesting requires stock price appreciation to $23.34-$62.24 per share

dilution

Risk Factors

  • Dilution risk if stock appreciates significantly and options vest
  • No material change to business fundamentals or financial outlook

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-347518
Document: 0001193125-26-347518-index-headers.html0001193125-26-347518
Document: 0001193125-26-347518-index.html0001193125-26-347518
Document: 0001193125-26-347518.txt0001193125-26-347518
9 reports for AGEN
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +138.65%May 11, 2026
Filters
Rows
Reports for AGEN — sortable, filterable
TypeNow
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 2/10
$7.00 $6.94▼ −0.86%▲ +0.89%$8.32 (+18.86%)
Aug 12, 2026
7w ago
Institutional Cluster
MIXED ★ 4/10
$6.90 $6.89▼ −0.14%▲ +1.75%$8.32 (+20.58%)
Aug 7, 2026
7w ago
S-3
BEARISH ★ 7/10
$7.00 $7.76▼ −10.87%▼ −11.78%$8.32 (−18.86%)
Aug 6, 2026
8w ago
8-K
NEUTRAL ★ 5/10
$7.49 $8.24▲ +10.01%▲ +9.41%$8.32 (+11.08%)
Jul 18, 2026
10w ago
S-3
BEARISH ★ 5/10
$4.97 $7.15▼ −43.86%▼ −39.74%$8.32 (−67.40%)
Jul 13, 2026
11w ago
8-K
BEARISH ★ 6/10
$6.12 $7.00▼ −14.38%▼ −11.19%$8.32 (−35.95%)
May 13, 2026
20w ago
DEFA14A
NEUTRAL ★ 4/10
$3.47 $3.39▼ −2.31%▼ −1.69%$8.32 (+139.77%)
May 11, 2026
20w ago
8-K
BULLISH ★ 7/10
$3.26 $3.11▼ −4.60%▼ −4.30%$8.32 (+155.21%)
Dec 4, 2025
43w ago
Court Ruling
BEARISH ★ 7/10
$4.06 $3.22▲ +20.69%▲ +21.18%$8.32 (−104.93%)
Showing 9 of 9

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access